Condition: Metastatic Breast Cancer · Sponsor: Japan Breast Cancer Research Group
The objective of this research is to evaluate the efficacy of the treatment strategy to administer atezolizumab + nab-paclitaxel (PTX) following 2 cycles of induction therapy with PTX + bevacizumab (induction treatment strategy) in programmed cell death ligand-1 (PD-L1)-positive metastatic triple-negative breast cancer (mTNBC) in comparison with the standard atezolizumab + nab-PTX therapy.
This description comes directly from the study's public registry record.
Yukinori Ozaki · +81-3-3520-0111 · yukinori.ozaki@jfcr.or.jp
Norikazu Masuda
Always discuss trial participation with your own doctor first.
| Yukinori Ozaki | Koto-ku, 3-8-31, Tokyo, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06793553